Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease

Kidney International

Volumn 83, Issue 5, 2013, Pages 959-966

  Hill, Kathleen M ^a   Martin, Berdine R ^b   Wastney, Meryl E ^b   McCabe, George P ^c   Moe, Sharon M ^a   Weaver, Connie M ^b   Peacock, Munro ^a  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PURDUE UNIVERSITY   (United States)

^c PURDUE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CALCI MIX; CALCIUM; CALCIUM CARBONATE; CREATININE; PHOSPHATE; PLACEBO; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CALCIUM ABSORPTION; CALCIUM BALANCE; CALCIUM BLOOD LEVEL; CALCIUM EXCRETION; CALCIUM MOBILIZATION; CALCIUM URINE LEVEL; CHRONIC KIDNEY DISEASE; CLINICAL ARTICLE; CONTROLLED STUDY; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; CROSSOVER PROCEDURE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; KIDNEY TUBULE ABSORPTION; MALE; OSSIFICATION; OSTEOLYSIS; PATIENT COMPLIANCE; PHOSPHATE BALANCE; PHOSPHATE BLOOD LEVEL; PHOSPHATE EXCRETION; PHOSPHATE URINE LEVEL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

EID: 84877027844     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/ki.2012.403     Document Type: Article

References (40)

1. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl 2009; 113: S1-130.
2. Nortman DF, Coburn JW. Renal osteodystrophy in end-stage renal failure. Postgrad Med 1978; 64: 123-130.
3. Coburn JW, Koppel MH, Brickman AS et al. Study of intestinal absorption of calcium in patients with renal failure. Kidney Int 1973; 3: 264-272.
4. Coburn JW, Hartenbower DL, Massry SG. Intestinal absorption of calcium and the effect of renal insufficiency. Kidney Int 1973; 4: 96-104.
5. Clarkson EM, Eastwood JB, Koutsaimanis KG et al. Net intestinal absorption of calcium in patients with chronic renal failure. Kidney Int 1973; 3: 258-263.
6. Francis RM, Peacock M, Barkworth SA. Renal impairment and its effects on calcium metabolism in elderly women. Age Ageing 1984; 13: 14-20.
7. Peacock M, Aaron JE, Walker GS et al. Bone disease and hyperparathyroidism in chronic renal failure: the effect of 1alphahydroxyvitamin D3. Clin Endocrinol 1977; (7 Suppl): 73s-81s.
8. Slatopolsky E, Brown A, Dusso A. Role of phosphorus in the pathogenesis of secondary hyperparathyroidism. Am J Kidney Dis 2001; 37: S54-S57.
9. Gutierrez O, Isakova T, Rhee E et al. Fibroblast growth factor-23 mitigates hyperphosphatemia but accentuates calcitriol deficiency in chronic kidney disease. J Am Soc Nephrol 2005; 16: 2205-2215.
10. Isakova T, Wahl P, Vargas GS et al. Fibroblast growth factor 23 is elevated before parathyroid hormone and phosphate in chronic kidney disease. Kidney Int 2011; 79: 1370-1378.
11. Levin A, Bakris GL, Molitch M et al. Prevalence of abnormal serum vitamin D, PTH, calcium, and phosphorus in patients with chronic kidney disease: results of the study to evaluate early kidney disease. Kidney Int 2007; 71: 31-38.
12. Kestenbaum B, Sampson JN, Rudser KD et al. Serum phosphate levels and mortality risk among people with chronic kidney disease. J Am Soc Nephrol 2005; 16: 520-528.
13. Slatopolsky E, Rutherford WE, Rosenbaum R et al. Hyperphosphatemia. Clin Nephrol 1977; 7: 138-146.
14. Slatopolsky E, Weerts C, Lopez-Hilker S et al. Calcium carbonate as a phosphate binder in patients with chronic renal failure undergoing dialysis. N Engl J Med 1986; 315: 157-161.
15. Alem AM, Sherrard DJ, Gillen DL et al. Increased risk of hip fracture among patients with end-stage renal disease. Kidney Int 2000; 58: 396-399.
16. Ensrud KE, Lui LY, Taylor BC et al. Renal function and risk of hip and vertebral fractures in older women. Arch Intern Med 2007; 167: 133-139.
17. Moe SM, Chertow GM. The case against calcium-based phosphate binders. Clin J Am Soc Nephrol 2006; 1: 697-703.
18. Moorthi RN, Moe SM. CKD-mineral and bone disorder: core curriculum2011. Am J Kidney Dis 2011; 58: 1022-1036.
19. Spiegel DM, Brady K. Calcium balance in normal individuals and in patients with chronic kidney disease on low-and high-calcium diets. Kidney Int 2012; 81: 1116-1122.
20. National Kidney Foundation. K/DOQI clinical practice guidelines for bone metabolism and disease in chronic kidney disease. Am J Kidney Dis 2003; 42: S1-201.
21. Spence LA, Lipscomb ER, Cadogan J et al. The effect of soy protein and soy isoflavones on calcium metabolism in postmenopausal women: a randomized crossover study. Am J Clin Nutr 2005; 81: 916-922.
22. Ross AC, Taylor CL, Yaktine AL et al. (eds) Institute of Medicine. Dietary Reference Intakes for Calcium and Vitamin D. National Academy Press 2011.
23. Calvo MS, Park YK. Changing phosphorus content of the U.S. diet: potential for adverse effects on bone. J Nutr 1996; 126: 1168S-1180S.
24. Russo D, Miranda I, Ruocco C et al. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int 2007; 72: 1255-1261.
25. Martin BR, Davis S, Campbell WW et al. Exercise and calcium supplementation: effects on calcium homeostasis in sportswomen. Med Sci Sport Exer 2007; 39: 1481-1486.
26. Dormaar JF, Webster GR. Determination of total organic phosphorus in soil by extraction methods. Can J Soil Sci 1964; 43: 35-43.
27. Yokota T, Ito T, Saigusa M. Measurement of total phosphorus and organic phosphorus contents of animal manure composts by the dry combustion method. Soil Sci Plant Nutr 2003; 49: 267-272.
28. Koiwa F, Kazama JJ, Tokumoto A et al. Sevelamer hydrochloride and calcium bicarbonate reduce serum fibroblast growth factor 23 levels in dialysis patients. Ther Apher Dial 2005; 9: 336-339.
29. Oliveira RB, Cancela AL, Graciolli FG et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5: 286-291.
30. Harris JA, Benedict FGA. Biometric Study of Human Basal Metabolism. Proc Natl Acad Sci USA 1918; 4: 370-373.
31. Wilkinson R. Polyethylene glycol 4000 as a continuously administered non-absorbable faecal marker for metabolic balance studies in human subjects. Gut 1971; 12: 654-660.
32. Weaver CM. Clinical approaches for studying calcium metabolism and its relationship to disease. In: Weaver CM, Heaney RP (eds). Calcium in Human Health. Humana Press: Totowa, NJ, 2006, pp 65-81.
33. Berman M. A postulate to aid in model building. J Theor Biol 1963; 4: 229-236.
34. Greif P, Wastney M, Linares O et al. Balancing needs, efficiency, and functionality in the provision of modeling software: a perspective of the NIH WinSAAM Project. Adv Exp Med Biol 1998; 445: 3-20.
35. Wastney ME, Ng J, Smith D et al. Differences in calcium kinetics between adolescent girls and young women. Am J Physiol 1996; 271: R208-R216.
36. Fadem SZ, Rosenthal B. National Kidney Foundation GFR Calculator. In. http://www.kidney.org/professionals/kdoqi/gfr-calculator.cfm.
37. Levey AS, Coresh J, Greene T et al. Expressing the Modification of Diet in Renal Disease Study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007; 53: 766-772.
38. Walker GA. The one-sample t-test. Common Statistical Methods for Clinical Research with SASs Examples, 2nd edn SAS Institute: Cary, NC, 2002.
39. Kutner MHN, Christopher J, Neter J et al. Applied Linear Statistical Models, 5th edn. McGraw-Hill/Irwin: New York, NY, 2005.
40. Walker GA. The Crossover Design. Common Statistical Methods for Clinical Research with SASs Examples, 2nd edn SAS Institute: Cary, NC, 2002.